Related Experiment Video

Updated: Apr 20, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

Targets and molecular mechanisms of triptolide in cancer therapy

Cuicui Meng1, Hongcheng Zhu1, Hongmei Song1

  • 11 Bengbu Medical College, Bengbu 233000, China ; 2 Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 3 Department of Radiation Oncology, Lianyungang No. 2 People's Hospital, Lianyungang 222000, China.

Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|November 18, 2014
PubMed

Insights

Triptolide (TPL), a natural compound, shows promising anticancer effects by inhibiting cancer cell growth and metastasis. Early clinical trials suggest TPL

Area of Science:

  • Natural product drug discovery
  • Cancer biology
  • Pharmacology

Background:

  • Triptolide (TPL) is a natural compound with demonstrated anticancer properties in preclinical models.
  • TPL exhibits multifaceted anti-cancer mechanisms, including inhibition of cell proliferation and induction of apoptosis.
  • TPL has shown potential in enhancing the efficacy of existing cancer therapies.

Purpose of the Study:

  • To summarize the anticancer effects of Triptolide (TPL).
  • To review the molecular pathways and signaling molecules involved in TPL's anti-cancer activity.
  • To assess the clinical potential of TPL based on early-phase trials.

Main Methods:

  • Review of preclinical studies on Triptolide (TPL) in various cancer cell lines.
  • Analysis of molecular targets and signaling pathways implicated in TPL's efficacy.
  • Evaluation of data from Phase I clinical trials of TPL.

Main Results:

  • TPL effectively inhibits cancer cell proliferation, induces apoptosis, and suppresses tumor metastasis.
  • Key molecular targets include caspases, heat-shock proteins, NF-κB, and DNA repair factors.
  • TPL enhances chemoradiosensitivity and shows potential clinical value in Phase I trials.

Conclusions:

  • Triptolide (TPL) possesses significant anticancer potential through diverse mechanisms.
  • Further large-scale clinical trials are necessary to validate TPL's therapeutic efficacy and safety.
Keywords:
Triptolide (TPL/TL)antineoplasticcancerneoplasms

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
12.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
3.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K